BR9509975A - Formulação farmacêutica - Google Patents

Formulação farmacêutica

Info

Publication number
BR9509975A
BR9509975A BR9509975A BR9509975A BR9509975A BR 9509975 A BR9509975 A BR 9509975A BR 9509975 A BR9509975 A BR 9509975A BR 9509975 A BR9509975 A BR 9509975A BR 9509975 A BR9509975 A BR 9509975A
Authority
BR
Brazil
Prior art keywords
pct
pharmaceutical formulation
date jun
sec
formulation
Prior art date
Application number
BR9509975A
Other languages
English (en)
Inventor
Simon Philip Hiskett
Susan Ann Taylor
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of BR9509975A publication Critical patent/BR9509975A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
BR9509975A 1994-12-07 1995-12-07 Formulação farmacêutica BR9509975A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9424766.5A GB9424766D0 (en) 1994-12-07 1994-12-07 Pharmaceutical composition
PCT/GB1995/002865 WO1996017611A1 (en) 1994-12-07 1995-12-07 Pharmaceutical composition comprising lamotrigine

Publications (1)

Publication Number Publication Date
BR9509975A true BR9509975A (pt) 1998-06-09

Family

ID=10765604

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9509975A BR9509975A (pt) 1994-12-07 1995-12-07 Formulação farmacêutica

Country Status (19)

Country Link
US (1) US5861179A (pt)
EP (1) EP0797441B1 (pt)
JP (1) JP2977284B2 (pt)
CN (1) CN1174505A (pt)
AT (1) ATE213633T1 (pt)
AU (1) AU696406B2 (pt)
BR (1) BR9509975A (pt)
CA (1) CA2207284A1 (pt)
CZ (1) CZ171797A3 (pt)
DE (1) DE69525649T2 (pt)
ES (1) ES2172600T3 (pt)
FI (1) FI972434A7 (pt)
GB (1) GB9424766D0 (pt)
HU (1) HUT77367A (pt)
NO (1) NO972623L (pt)
NZ (1) NZ296573A (pt)
PL (1) PL320560A1 (pt)
RU (1) RU2160106C2 (pt)
WO (1) WO1996017611A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
DE19603984A1 (de) * 1996-02-05 1997-08-07 Bayer Ag Granulate von Triazinen
AU1970797A (en) * 1997-02-25 1998-09-09 Procter & Gamble Company, The Wet granulating method
EP1098636A1 (en) * 1998-07-23 2001-05-16 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation
CN1183240C (zh) * 1999-06-21 2005-01-05 宝洁公司 在不合格尺寸颗粒循环利用的流化床成粒机中制备粒状洗涤剂的方法
IL157608A0 (en) 2001-02-27 2004-03-28 Teva Pharma New crystal forms of lamotrigine and processes for their preparations
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
AU2003234240A1 (en) * 2002-04-23 2003-11-10 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
WO2004082587A2 (en) * 2003-03-21 2004-09-30 Ranbaxy Laboratories Limited Stable lamotrigine pharmaceutical compositions and processes for their preparation
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
ES2401769T5 (es) 2003-09-12 2020-07-01 Amgen Inc Formulación de disolución rápida de cinacalcet HCl
CA2567411A1 (en) * 2004-05-31 2005-12-08 Senju Pharmaceutical Co., Ltd. Transparent tissue-visualizing preparation
US20100016322A1 (en) * 2007-02-28 2010-01-21 Nagesh Nagaraju Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
MX2012010229A (es) 2010-03-04 2012-12-05 Wockhardt Ltd Forma de dosis de liberacion modificada.
EP3525792A4 (en) 2016-10-11 2020-04-22 Aucta Pharmaceuticals POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGIN
CN117442576A (zh) * 2023-11-21 2024-01-26 三金集团湖南三金制药有限责任公司 一种拉莫三嗪制剂组合物及其制备方法
US12605388B2 (en) 2024-09-25 2026-04-21 Azurity Pharmaceuticals Ireland Limited Lamotrigine salts, co-crystals, and compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
EP0021121B1 (en) * 1979-06-01 1983-05-11 The Wellcome Foundation Limited 1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
EP0406126B2 (en) * 1989-06-30 1997-12-17 Sumitomo Electric Industries, Ltd. Substrate having a superconductor layer
FI20021701L (fi) * 1991-01-30 2002-09-24 Wellcome Found Veteen dispergoituvia tabletteja
CA2277722C (en) * 1991-11-22 2001-03-27 The Wellcome Foundation Limited Water dispersible tablets
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2700114A1 (fr) * 1993-01-07 1994-07-08 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
GB9305693D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9305692D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
FR2702149B1 (fr) * 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement du neuro-sida.
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets

Also Published As

Publication number Publication date
RU2160106C2 (ru) 2000-12-10
NO972623L (no) 1997-08-06
CZ171797A3 (en) 1997-11-12
FI972434A0 (fi) 1997-06-06
CN1174505A (zh) 1998-02-25
WO1996017611A1 (en) 1996-06-13
EP0797441B1 (en) 2002-02-27
US5861179A (en) 1999-01-19
GB9424766D0 (en) 1995-02-08
EP0797441A1 (en) 1997-10-01
PL320560A1 (en) 1997-10-13
FI972434L (fi) 1997-06-09
HUT77367A (hu) 1998-03-30
AU4121196A (en) 1996-06-26
ATE213633T1 (de) 2002-03-15
AU696406B2 (en) 1998-09-10
NZ296573A (en) 1997-08-22
FI972434A7 (fi) 1997-06-09
DE69525649T2 (de) 2002-09-05
JP2977284B2 (ja) 1999-11-15
JPH10510255A (ja) 1998-10-06
CA2207284A1 (en) 1996-06-13
NO972623D0 (no) 1997-06-06
DE69525649D1 (de) 2002-04-04
ES2172600T3 (es) 2002-10-01
MX9704103A (es) 1997-09-30

Similar Documents

Publication Publication Date Title
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
BR9508655A (pt) Composição farmacêutica aquosa estéril
NO963053D0 (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
PT979244E (pt) Derivados de ciclosporina, sua preparacao e composicoes farmaceuticas que os contem
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
HU9603228D0 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
DE69532580D1 (de) Neue antagonistische verbindungen
BR9609847A (pt) Derivados de N-(4-Benzila-substituída)-2-aminolactam
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
SE9402880D0 (sv) New peptide derivatives
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
DE69521122D1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
SE9504662D0 (sv) New compounds
DK0678089T3 (da) N-Acylpyrrolidiner og lægemidler til behandling eller forebyggelse af cholecystokinin- og gastrin-relaterede forstyrrelser
BR9306870A (pt) Derivados farmacologicamente ativos de (aminometila terciária) - benzenometanol
SI0863752T1 (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases
SE9404438D0 (sv) New process
KR960700053A (ko) 방사선회복제로서 리루졸의 이용(application of riluzole as a radiorestorer)

Legal Events

Date Code Title Description
FB34 Technical and formal requirements: requirement - article 34 of industrial property law
FA14 Dismissal: dismissal - article 34 of industrial property law
B11T Dismissal of application maintained [chapter 11.20 patent gazette]